Omniose
PrivateLast Round
Grant
Sep 27, 2023
Total Funding Raised
$12.65M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Omniose operates in Healthcare & Life Sciences and is based in Saint Louis, Michigan. Its latest recorded funding round was a Grant round in September 2023.
Omniose is a biotechnology company that develops polysaccharide conjugate vaccines against bacterial threats using its proprietary bioconjugation platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Omniose Comparables
Compare Omniose with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| LimmaTech Biologics | 85% | |
| Baxiva AG | 85% | |
| Glycovax Pharma | 83% |
For institutional investors. Book with your work email.
Omniose Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Sep 27, 2023 | ||||
| Grant | Oct 11, 2022 | ||||
| Grant | Aug 20, 2020 | ||||
| Grant | Feb 21, 2020 | ||||
| Seed | Jan 1, 2019 | ||||
Grant | Nov 3, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Omniose Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| Arch Grants | Grant |
| NIH RADx | Grant |
| BioGenerator Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 115% MoM, from 1.4K to 3.1K.
- Sep 27, 2023
$3M raised from National Institute of Allergy and Infectious Diseases
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 11, 2026
Omniose is developing a bioconjugate platform to create vaccines against multidrug-resistant superbugs as antimicrobial resistance rises.
- receives_financingNov 11, 2026
By Sep '26, Omniose reports raising $14.5M, almost all through non-dilutive grants from the National Institutes of Health and an Arch Grants award, while AstraZeneca provides additional undisclosed resources during their research partnership.
For institutional investors. Book with your work email.
Omniose Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Omniose's valuation, stock price, and market status.
Is Omniose a public or private company?
Omniose is a private company.
What is the current stock price of Omniose?
Omniose is a private company, so its shares have no public market price. Caplight tracks Omniose's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Omniose worth (valuation)?
Valuation information for Omniose is not publicly available.
Can I buy Omniose stock?
Omniose shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Omniose's last funding round?
Omniose's most recent funding round was Grant on September 27, 2023.
Who are the main investors in Omniose?
Key investors in Omniose include National Institute of Allergy and Infectious Diseases, Arch Grants, NIH RADx, BioGenerator Ventures.
Will Omniose IPO soon?
No public IPO plans have been announced for Omniose.
How can I track Omniose secondary market activity?
Caplight tracks bids, offers, and trades in Omniose's shares on secondary markets.